

Consolidated Statement of Profit or Loss

Sumitomo Pharma Co., Ltd. and Consolidated Subsidiaries Years Ended March 31, 2022 and 2021

	Millions of yen	
	2021	2022
Revenue	¥ 515,952	¥ 560,035
Cost of sales	137,773	157,127
Gross profit	378,179	402,908
Selling, general and administrative expenses	190,373	249,081
Research and development expenses	132,682	94,903
Other income	17,662	2,406
Other expenses	1,562	1,096
Operating profit	71,224	60,234
Finance income	9,213	25,777
Finance costs	2,586	3,050
Profit before taxes	77,851	82,961
Income tax expenses	41,022	42,361
Net profit	36,829	40,600
Net profit attributable to:		
Owners of the parent	56,219	56,413
Non-controlling interests	(19,390)	(15,813)
Net profit total	36,829	40,600
Earnings per share (yen)		
Basic earnings per share	141.50	141.99

Consolidated Statement of Comprehensive Income

Sumitomo Pharma Co., Ltd. and Consolidated Subsidiaries Years Ended March 31, 2022 and 2021

	Millions of yen	
	2021	2022
Net profit	¥ 36,829	¥ 40,600
Other comprehensive income		
Items that will not be reclassified to profit or loss:		
Net gain (loss) on revaluation of financial assets measured at fair value through other comprehensive income	(7,621)	(56,800)
Remeasurements of defined benefit liability (asset)	6,330	2,307
Items that may be reclassified subsequently to profit or loss:		
Exchange differences on translation of foreign operations	5,367	42,004
Cash flow hedges	102	50
Total other comprehensive income	4,178	(12,439)
Total comprehensive income	41,007	28,161
Total comprehensive income attributable to:		
Owners of the parent	61,008	37,574
Non-controlling interests	(20,001)	(9,413)
Total comprehensive income	41,007	28,161

Consolidated Statement of Financial Position

Sumitomo Pharma Co., Ltd. and Consolidated Subsidiaries Years Ended March 31, 2022 and 2021

Millions of yen

	2021	2022
Assets		
Non-current assets		
Property, plant and equipment	¥ 64,966	¥ 64,091
Goodwill	176,492	195,144
Intangible assets	383,406	398,692
Other financial assets	193,035	115,844
Income taxes receivables	6,726	5,538
Other non-current assets	3,516	6,527
Deferred tax assets	20,191	22,650
Total non-current assets	848,332	808,486
Current assets		
Inventories	92,215	99,021
Trade and other receivables	135,866	151,407
Other financial assets	29,480	35,596
Income taxes receivables	194	93
Other current assets	8,342	10,420
Cash and cash equivalents	193,698	202,984
Total current assets	459,795	499,521
Total assets	1,308,127	1,308,007
Liabilities and equity		
Liabilities		
Non-current liabilities		
Bonds and Borrowings	263,859	243,963
Other financial liabilities	21,404	16,471
Retirement benefit liabilities	15,069	11,461
Other non-current liabilities	53,046	57,620
Deferred tax liabilities	28,424	26,550
Total non-current liabilities	381,802	356,065
Current liabilities		
Borrowings	9,960	25,085
Trade and other payables	64,638	46,183
Other financial liabilities	23,341	13,302
Income taxes payable	24,511	7,583
Provisions	99,851	119,149
Other current liabilities	55,846	67,071
Total current liabilities	278,147	278,373
Total liabilities	659,949	634,438
Equity		
Share capital	22,400	22,400
Capital surplus	15,855	16,725
Treasury shares	(679)	(681)
Retained earnings	508,677	514,210
Other components of equity	34,317	55,234
Equity attributable to owners of the parent	580,570	607,888
Non-controlling interests	67,608	65,681
Total equity	648,178	673,569
Total liabilities and equity	¥ 1,308,127	¥ 1,308,007

Consolidated Statement of Changes in Equity

Sumitomo Pharma Co., Ltd. and Consolidated Subsidiaries Years Ended March 31, 2022 and 2021

Millions of yen

	Equity attributable to owners of the parent				Other components of equity	
	Share capital	Capital surplus	Treasury shares	Retained earnings	Net gain (loss) on revaluation of financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit liability (asset)
Balance as of April 1, 2020	¥ 22,400	¥ 17,837	¥ (677)	¥ 457,330	¥ 46,118	¥ —
Net profit	—	—	—	56,219	—	—
Other comprehensive income	—	—	—	—	(7,621)	6,330
Total comprehensive income	—	—	—	56,219	(7,621)	6,330
Purchase of treasury shares	—	—	(2)	—	—	—
Dividends	—	—	—	(11,124)	—	—
Transactions with non-controlling interests	—	(1,982)	—	—	—	—
Reclassification from other components of equity to retained earnings	—	—	—	6,252	78	(6,330)
Other increase/decrease	—	—	—	—	—	—
Total transactions with owners	—	(1,982)	(2)	(4,872)	78	(6,330)
Balance as of March 31, 2021	¥ 22,400	¥ 15,855	¥ (679)	¥ 508,677	¥ 38,575	¥ —
Net profit	—	—	—	56,413	—	—
Other comprehensive income	—	—	—	—	(56,800)	2,307
Total comprehensive income	—	—	—	56,413	(56,800)	2,307
Purchase of treasury shares	—	—	(2)	—	—	—
Dividends	—	—	—	(11,124)	—	—
Transactions with non-controlling interests	—	870	—	—	—	—
Reclassification from other components of equity to retained earnings	—	—	—	(39,756)	42,063	(2,307)
Other increase/decrease	—	—	—	—	—	—
Total transactions with owners	—	870	(2)	(50,880)	42,063	(2,307)
Balance as of March 31, 2022	¥ 22,400	¥ 16,725	¥ (681)	¥ 514,210	¥ 23,838	¥ —

Millions of yen

	Equity attributable to owners of the parent			Total	Non-controlling interests	Total equity
	Other components of equity					
	Exchange differences on translation of foreign operations	Cash flow hedges	Total			
Balance as of April 1, 2020	¥ (10,309)	¥ (29)	¥ 35,780	¥ 532,670	¥ 103,190	¥ 635,860
Net profit	—	—	—	56,219	(19,390)	36,829
Other comprehensive income	5,978	102	4,789	4,789	(611)	4,178
Total comprehensive income	5,978	102	4,789	61,008	(20,001)	41,007
Purchase of treasury shares	—	—	—	(2)	—	(2)
Dividends	—	—	—	(11,124)	—	(11,124)
Transactions with non-controlling interests	—	—	—	(1,982)	(15,630)	(17,612)
Reclassification from other components of equity to retained earnings	—	—	(6,252)	—	—	—
Other increase/decrease	—	—	—	—	49	49
Total transactions with owners	—	—	(6,252)	(13,108)	(15,581)	(28,689)
Balance as of March 31, 2021	¥ (4,331)	¥ 73	¥ 34,317	¥ 580,570	¥ 67,608	¥ 648,178
Net profit	—	—	—	56,413	(15,813)	40,600
Other comprehensive income	35,604	50	(18,839)	(18,839)	6,400	(12,439)
Total comprehensive income	35,604	50	(18,839)	37,574	(9,413)	28,161
Purchase of treasury shares	—	—	—	(2)	—	(2)
Dividends	—	—	—	(11,124)	—	(11,124)
Transactions with non-controlling interests	—	—	—	870	7,486	8,356
Reclassification from other components of equity to retained earnings	—	—	39,756	—	—	—
Other increase/decrease	—	—	—	—	—	—
Total transactions with owners	—	—	39,756	(10,256)	7,486	(2,770)
Balance as of March 31, 2022	¥ 31,273	¥ 123	¥ 55,234	¥ 607,888	¥ 65,681	¥ 673,569

Consolidated Statement of Cash Flows

Sumitomo Pharma Co., Ltd. and Consolidated Subsidiaries Years Ended March 31, 2022 and 2021

Millions of yen

	2021	2022
Cash flows from operating activities		
Net profit	¥ 36,829	¥ 40,600
Depreciation and amortization	22,673	38,348
Impairment losses	35,720	910
Changes in fair value of contingent consideration	(22,463)	(3,282)
Loss (gain) on sales of property, plant and equipment	(16,731)	(141)
Interest and dividend income	(1,153)	(1,175)
Interest expenses	2,436	2,970
Income tax expenses	41,022	42,361
(Increase) decrease in trade and other receivables	185	(6,097)
(Increase) decrease in inventories	(10,039)	5,356
Increase (decrease) in trade and other payables	(320)	(28,669)
Increase (decrease) in unearned revenue	51,067	(469)
Increase (decrease) in other financial liabilities	12,001	(11,540)
Increase (decrease) in retirement benefits liabilities	288	(348)
Increase (decrease) in provisions	13,145	8,034
Others, net	7,042	(11,953)
Subtotal	171,702	74,905
Interest received	221	173
Dividends received	942	992
Interest paid	(2,229)	(2,500)
Income taxes paid	(35,035)	(42,331)
Net cash provided by operating activities	135,601	31,239
Cash flows from investing activities		
Purchase of property, plant and equipment	(6,048)	(7,347)
Proceeds from sales of property, plant and equipment	21,520	1,313
Purchase of intangible assets	(4,758)	(6,147)
Purchase of investments	(9,366)	(25,905)
Proceeds from sales and redemption of investments	8,141	19,472
Net decrease (increase) in short-term loan receivables	(839)	1,133
Others, net	225	(797)
Net cash provided by (used in) investing activities	8,875	(18,278)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	(265,000)	29
Proceeds from long-term borrowings	125,000	—
Repayments of long-term borrowings	(2,960)	(4,960)
Proceeds from issuance of corporate bonds	118,927	—
Repayments of lease liabilities	(4,727)	(4,499)
Dividends paid	(11,120)	(11,126)
Payments for acquisition of interest in a subsidiary from non-controlling interests	(19,300)	(3,636)
Others, net	1,965	2,766
Net cash provided by (used in) financing activities	(57,215)	(21,426)
Net increase (decrease) in cash and cash equivalents	87,261	(8,465)
Cash and cash equivalents at beginning of year	101,708	193,698
Effect of exchange rate changes on cash and cash equivalents	4,729	17,751
Cash and cash equivalents at end of year	¥ 193,698	¥ 202,984